XML 37 R20.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Stock Plans and Stock Based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract] |
Stock Plans and Stock Based Compensation | Stock Plans and Stock-Based Compensation In 2019, the 2009 Tompkins Financial Corporation Equity Plan ("2009 Equity Plan") expired and was replaced by the new Tompkins Financial Corporation 2019 Equity Plan ("2019 Equity Plan"). Under the 2019 Equity Plan, the Company may grant stock options, stock appreciation rights ("SARs"), shares of restricted stock, restricted units and performance share awards covering up to 2,275,000 shares of the Company's common stock to certain officers and employees. Restricted stock awards and restricted units and performance share awards will reduce the shares available for grant under the 2019 Equity Plan by 4.25 shares for each share subject to an award, resulting in a total number of full-value share awards that may be issued under the 2019 Equity Plan to 535,294. Stock options and SARs are granted at an exercise price equal to the stock’s fair value at the date of grant, may not have a term in excess of ten years, and have vesting periods of five and seven years from the grant date. Options and SARs with an expiration date in 2026 have a five-year vesting schedule with zero percent vesting in year one and 25% vesting in years two through five. All other options and SARs have a seven-year vesting schedule with zero percent vesting in year one, 17% vesting in years two through six and 15% vesting in year seven. Restricted stock awards and restricted stock units that were granted in the periods covering 2019 through 2024 have a five-year vesting schedule with zero percent vesting in year one and 25% vesting in years two through five. For performance share awards, there is a 3-year performance period in the fiscal years immediately following the grant date, at which time the performance goal is measured. If the goal is achieved, the value of the award either vests and is immediately payable, or is subject to additional time-based vesting, depending on the terms of the particular executive’s award agreement. The Company granted 84,019 equity awards to its employees in 2024, consisting of 57,060 shares of restricted stock, 19,929 performance stock units and 7,030 restricted stock units. The Company granted 120,116 equity awards to its employees in 2023, consisting of 79,140 shares of restricted stock, 28,346 performance share units and 12,630 restricted stock units. The following table presents the activity related to stock options and SARs under the Company's 2009 Equity Plan and 2019 Equity Plan for the year ended December 31, 2024:
| Number of Shares/Rights | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term | Aggregate Intrinsic Value
Outstanding at January 1, 2024 | 48,882 |  | $ | 59.13 |  |  |
Granted | 0 |  | 0.00 |  |  |
Exercised | (18,325) |  | 50.21 |  |  |
Forfeited | (10,536) |  | 60.60 |  |  |
Outstanding at December 31, 2024 | 20,021 |  | $ | 66.51 |  | 1.23 | $ | 131,642 |
Exercisable at December 31, 2024 | 20,021 |  | $ | 66.51 |  | 1.23 | $ | 131,642 |
Total stock-based compensation expense for stock options and SARs was $0 in 2024, $0 in 2023, and $33,000 in 2022. As of December 31, 2024, unrecognized compensation cost related to unvested stock options and SARs totaled $0. Net cash proceeds, tax benefits and intrinsic value related to total stock options, SARs, and restricted stock exercised is as follows:
(In thousands) | 2024 | 2023 | 2022
Proceeds from stock option exercises | $ | (115) |  | $ | (124) |  | $ | (538) |
Tax benefits related to stock option exercises | (134) |  | (229) |  | 196 |
Intrinsic value of stock option exercises | 132 |  | 270 |  | 1,075 |
The Company uses the Black-Scholes option-valuation model to determine the fair value of incentive stock options and SARs at the date of grant. The valuation model estimates fair value based on the assumptions for the risk-free rate, expected dividend yield, volatility and expected life. The risk-free rate is the interest rate available on zero-coupon U.S. Treasury instruments with a remaining term equal to the expected term of the share option at the time of grant. The expected dividend yield is based on the dividend trends and the market price of the Company’s stock price at grant. Volatility is largely based on historical volatility of the Company’s stock price. The expected term is based upon historical experience of employee exercises and terminations as the vesting term of the grants. The fair values of the grants are expensed over the vesting periods. There were no incentive stock options or SARs granted in 2024, 2023 or 2022.
December 31, 2024 |  |  |
Options and SARs Outstanding | Options and SARs Exercisable
Range of Exercise Prices | Number Outstanding | Weighted Average Remaining Contractual Life | Weighted Average Exercise Price | Number Exercisable | Weighted Average Exercise Price
$50.01-76.90 | 19,799 |  | 1.22 | $ | 66.29 |  | 19,799 |  | $ | 66.29 |
$76.91-86.18 | 222 |  | 1.89 | $ | 86.18 |  | 222 |  | $ | 86.18 |
| 20,021 |  | 1.23 | $ | 66.51 |  | 20,021 |  | $ | 66.51 |
The following table presents activity related to restricted stock awards and restricted stock units for the year ended December 31, 2024:
| Number of Shares | Weighted Average Grant Date Fair Value
Unvested at January 1, 2024 | 269,913 |  | $ | 63.22 |
Granted | 84,019 |  | 72.29 |
Vested | (53,779) |  | 76.59 |
Forfeited | (18,556) |  | 66.78 |
Unvested at December 31, 2024 | 281,597 |  | $ | 62.33 |
The Company granted 57,060 restricted stock awards, 7,030 restricted stock units, and 19,929 performance units in 2024, each at an average grant date fair value of $72.29. The Company granted 79,140 restricted stock awards, 12,630 restricted stock units, and 28,346 performance units in 2023, each at an average grant date fair value of $51.02. The Company granted 50,155 restricted stock awards, 8,215 restricted stock units, 16,284 performance units and 2,615 performance share awards in 2022 at an average grant date fair value of $81.48. The grant date fair values were the closing prices of the Company’s common stock on the grant dates. The Company recognized stock-based compensation related to restricted stock awards, restricted stock units, and performance share awards of $4.6 million in 2024, $4.4 million in 2023, and $4.8 million in 2022. Unrecognized compensation costs related to restricted stock and performance awards totaled $10.0 million, and restricted stock units totaled $1.3 million at December 31, 2024 and will be recognized over 3.5 years and 3.8 years, respectively on a weighted average basis.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration